IRIS Accounts Production v23.3.1.45 13118677 Board of Directors Board of Directors Board of Directors 1.4.22 31.3.23 31.3.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh131186772022-03-31131186772023-03-31131186772022-04-012023-03-31131186772021-01-06131186772021-01-072022-03-31131186772022-03-3113118677ns10:Originalns15:EnglandWales2022-04-012023-03-3113118677ns14:PoundSterlingns10:Original2022-04-012023-03-3113118677ns10:Originalns10:Director12022-04-012023-03-3113118677ns10:Original2022-04-012023-03-3113118677ns10:Originalns10:Director22022-04-012023-03-3113118677ns10:Originalns10:Director32022-04-012023-03-3113118677ns10:Original2023-03-3113118677ns10:Originalns10:PrivateLimitedCompanyLtd2022-04-012023-03-3113118677ns10:Originalns10:SmallEntities2022-04-012023-03-3113118677ns10:Originalns10:AuditExempt-NoAccountantsReport2022-04-012023-03-3113118677ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-04-012023-03-3113118677ns10:SmallCompaniesRegimeForAccountsns10:Original2022-04-012023-03-3113118677ns10:Originalns10:FullAccounts2022-04-012023-03-3113118677ns10:Originalns10:RegisteredOffice2022-04-012023-03-3113118677ns10:Original2022-03-3113118677ns10:Originalns5:CurrentFinancialInstruments2023-03-3113118677ns10:Originalns5:CurrentFinancialInstruments2022-03-3113118677ns5:ShareCapitalns10:Original2023-03-3113118677ns5:ShareCapitalns10:Original2022-03-3113118677ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-03-3113118677ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-03-3113118677ns10:Original2021-01-072022-03-3113118677ns10:Originalns5:CostValuation2022-03-3113118677ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3113118677ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-03-31
REGISTERED NUMBER: 13118677 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2023

for

ABTI Pharma Limited

ABTI Pharma Limited (Registered number: 13118677)






Contents of the Financial Statements
for the Year Ended 31 March 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


ABTI Pharma Limited

Company Information
for the Year Ended 31 March 2023







DIRECTORS: T P Rogers
C Stott
D C Schiller





REGISTERED OFFICE: Bretton House
Bell Meadow Business Park
Park Lane
Pulford
Chester
CH4 9EP





REGISTERED NUMBER: 13118677 (England and Wales)





ACCOUNTANTS: DUNCAN BOXWELL & COMPANY LIMITED
Bretton House
Bell Meadow Business Park
Pulford
Chester
Cheshire
CH4 9EP

ABTI Pharma Limited (Registered number: 13118677)

Balance Sheet
31 March 2023

31.3.23 31.3.22
Notes £    £    £    £   
FIXED ASSETS
Investments 4 3 3

CURRENT ASSETS
Debtors 5 30,840 100,722
Cash at bank 1,249 5,293
32,089 106,015
CREDITORS
Amounts falling due within one year 6 901,441 470,250
NET CURRENT LIABILITIES (869,352 ) (364,235 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(869,349

)

(364,232

)

PROVISIONS FOR LIABILITIES 22,750 -
NET LIABILITIES (892,099 ) (364,232 )

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings (892,199 ) (364,332 )
(892,099 ) (364,232 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

ABTI Pharma Limited (Registered number: 13118677)

Balance Sheet - continued
31 March 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 March 2024 and were signed on its behalf by:




D C Schiller - Director T P Rogers - Director




C Stott - Director


ABTI Pharma Limited (Registered number: 13118677)

Notes to the Financial Statements
for the Year Ended 31 March 2023

1. STATUTORY INFORMATION

ABTI Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2022 - 5 ) .

ABTI Pharma Limited (Registered number: 13118677)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 April 2022
and 31 March 2023 3
NET BOOK VALUE
At 31 March 2023 3
At 31 March 2022 3

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.23 31.3.22
£    £   
Other debtors 30,840 100,722

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.23 31.3.22
£    £   
Trade creditors 286,565 229,401
Amounts owed to group undertakings 222,920 -
Taxation and social security 13,020 3,858
Other creditors 378,936 236,991
901,441 470,250

7. ULTIMATE CONTROLLING PARTY

The company is wholly owned by Alterola Biotech, Inc., a company incorporated in the State of Nevada in U.S. on July 21, 2008 under the name 'Jedediah Resources Corp'.

8. GOING CONCERN

At the year end, the company’s balance sheet showed net current liabilities. This indicates that the company is technically insolvent and could be wound up on the petition of creditors.

The directors and shareholders have indicated their ongoing financial support. The accounts have been prepared on a going concern basis to reflect this.